|
G |
Abce1 |
ATP binding cassette subfamily E member 1 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of ABCE1 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr19:28,205,566...28,230,489
Ensembl chr19:28,205,555...28,230,489
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of ANXA1 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of BIRC2 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases activity |
ISO |
Thiophenes analog results in decreased activity of CA1 protein |
CTD |
PMID:30537031 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
Thiophenes analog results in decreased activity of CA2 protein |
CTD |
PMID:30537031 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Cd53 |
Cd53 molecule |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of CD53 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 2:194,352,139...194,399,668
Ensembl chr 2:194,352,139...194,399,657
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of CDKN1A protein] |
CTD |
PMID:16140954 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of CDKN1B protein] |
CTD |
PMID:16140954 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cse1l |
chromosome segregation 1 like |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of CSE1L mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865
|
|
G |
Ddx10 |
DEAD-box helicase 10 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of DDX10 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 8:53,488,656...53,643,373
Ensembl chr 8:53,488,656...53,643,373
|
|
G |
Ddx18 |
DEAD-box helicase 18 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of DDX18 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr13:32,729,697...32,743,161
Ensembl chr13:32,729,700...32,743,161
|
|
G |
Eif3b |
eukaryotic translation initiation factor 3, subunit B |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of EIF3B mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr12:14,196,403...14,220,865
Ensembl chr12:14,196,403...14,220,886
|
|
G |
Eif3c |
eukaryotic translation initiation factor 3, subunit C |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of EIF3C mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 1:181,134,604...181,152,489
Ensembl chr 1:181,134,604...181,152,493
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of EIF4E mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of EIF4EBP1 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Gas7 |
growth arrest specific 7 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of GAS7 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276
|
|
G |
Grb10 |
growth factor receptor bound protein 10 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of GRB10 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr14:86,495,051...86,602,800
Ensembl chr14:86,495,054...86,602,806
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of GSTP1 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hdac1 |
histone deacetylase 1 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of HDAC1 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions |
ISO |
Thiophenes analog binds to and results in decreased activity of HRH3 protein |
CTD |
PMID:16616493 |
|
NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of IFIT3 mRNA] |
CTD |
PMID:16140954 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Ifitm1 |
interferon induced transmembrane protein 1 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of IFITM1 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Thiophenes inhibits the reaction [KEAP1 gene mutant form promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]] |
CTD |
PMID:23906629 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga6 |
integrin subunit alpha 6 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of ITGA6 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
Thiophenes inhibits the reaction [KEAP1 gene mutant form promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]] |
CTD |
PMID:23906629 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of LAMP2 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Ly6e |
lymphocyte antigen 6 family member E |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of LY6E mRNA] |
CTD |
PMID:16140954 |
|
NCBI chr 7:106,935,530...106,939,689
Ensembl chr 7:106,935,761...106,939,689
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of MPO mRNA] |
CTD |
PMID:16140954 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of MYC mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh9 |
myosin, heavy chain 9 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of MYH9 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 7:109,343,718...109,424,457
Ensembl chr 7:109,343,706...109,424,457
|
|
G |
Nae1 |
NEDD8 activating enzyme E1 subunit 1 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of NAE1 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr19:446,015...472,145
Ensembl chr19:446,000...472,371
|
|
G |
Nmi |
N-myc (and STAT) interactor |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of NMI mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:36,415,607...36,439,498
|
|
G |
Ppm1g |
protein phosphatase, Mg2+/Mn2+ dependent, 1G |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of PPM1G mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 6:25,153,556...25,173,763
Ensembl chr 6:25,153,556...25,173,761
|
|
G |
Prmt1 |
protein arginine methyltransferase 1 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of PRMT1 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345
|
|
G |
Rabggtb |
Rab geranylgeranyltransferase subunit beta |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of RABGGTB mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 2:242,844,758...242,850,951
Ensembl chr 2:242,844,762...242,851,050
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of RARA mRNA alternative form] |
CTD |
PMID:16140955 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased phosphorylation of RB1 protein] |
CTD |
PMID:16140954 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rig1 |
RNA sensor RIG-1 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of RIGI mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 5:55,321,351...55,369,947
Ensembl chr 5:55,321,235...55,370,819
|
|
G |
Ruvbl2 |
RuvB-like AAA ATPase 2 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in decreased expression of RUVBL2 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 1:95,902,014...95,915,247
Ensembl chr 1:95,901,701...95,915,342
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of STAT1 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stk10 |
serine/threonine kinase 10 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of STK10 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr10:17,117,860...17,212,065
Ensembl chr10:17,117,878...17,212,061
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of TGM2 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
Thiophenes analog promotes the reaction [Tretinoin results in increased expression of TNFSF10 mRNA] |
CTD |
PMID:16140955 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:38701902 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Duloxetine Hydrochloride binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Cd48 |
Cd48 molecule |
multiple interactions |
EXP |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in increased expression of CD48 protein] |
CTD |
PMID:38701902 |
|
NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases activity multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of CYP17A1 protein Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Pregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Progesterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] |
CTD |
PMID:29100959 |
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[furafylline results in decreased activity of CYP1A2 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP1A2 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride |
CTD |
PMID:20669986 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
EXP |
[Quinidine results in decreased activity of CYP2D6 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP2D6 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride |
CTD |
PMID:20669986 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Duloxetine Hydrochloride results in increased expression of HMOX1 mRNA |
CTD |
PMID:29134401 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in increased expression of IL1A protein] |
CTD |
PMID:38701902 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA]; Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124
|
|
G |
Kcnj5 |
potassium inwardly-rectifying channel, subfamily J, member 5 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr 8:30,724,923...30,753,083
Ensembl chr 8:30,724,925...30,753,518
|
|
G |
Kcnj6 |
potassium inwardly-rectifying channel, subfamily J, member 6 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
ISO |
Duloxetine Hydrochloride affects the localization of NFE2L2 protein |
CTD |
PMID:29134401 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Duloxetine Hydrochloride results in increased expression of PRL protein |
CTD |
PMID:17606668 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in decreased expression of VEGFA protein] |
CTD |
PMID:38701902 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] |
CTD |
PMID:32687258 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
Carticaine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] |
CTD |
PMID:32687258 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases secretion |
ISO |
Carticaine results in increased secretion of CALCA protein |
CTD |
PMID:18172555 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein] |
CTD |
PMID:32687258 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:32687258 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:32687258 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Carticaine inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein] |
CTD |
PMID:32687258 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of MYD88 protein] |
CTD |
PMID:32687258 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Carticaine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:32687258 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein] |
CTD |
PMID:32687258 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Carticaine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] |
CTD |
PMID:32687258 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein] |
CTD |
PMID:32687258 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:32687258 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases activity |
EXP |
Carticaine results in increased activity of TRPV1 protein |
CTD |
PMID:18172555 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
arotinolol promotes the reaction [Thyroxine results in decreased expression of CAT protein] |
CTD |
PMID:2575990 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
decreases activity multiple interactions |
ISO |
azosemide results in decreased activity of SLC12A2 protein azosemide inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium] |
CTD |
PMID:15517342 PMID:29959396 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
batimastat results in decreased metabolism of and results in decreased secretion of ACHE protein |
CTD |
PMID:23047022 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Areg |
amphiregulin |
decreases secretion multiple interactions |
ISO |
batimastat results in decreased secretion of AREG protein batimastat inhibits the reaction [pervanadate results in increased cleavage of AREG protein]; batimastat inhibits the reaction [Tetrachlorodibenzodioxin results in increased secretion of AREG protein] |
CTD |
PMID:9685416 PMID:27117977 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
ISO |
batimastat inhibits the reaction [pervanadate results in increased cleavage of ERBB4 protein] |
CTD |
PMID:9685416 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ereg |
epiregulin |
multiple interactions |
ISO |
batimastat inhibits the reaction [Tetrachlorodibenzodioxin results in increased secretion of EREG protein] |
CTD |
PMID:27117977 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
decreases activity |
ISO |
batimastat results in decreased activity of FURIN protein |
CTD |
PMID:15632106 |
|
NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314
|
|
G |
Il5ra |
interleukin 5 receptor subunit alpha |
decreases cleavage |
ISO |
batimastat results in decreased cleavage of IL5RA protein |
CTD |
PMID:12444155 |
|
NCBI chr 4:139,630,652...139,664,593
Ensembl chr 4:139,632,066...139,668,544
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases activity multiple interactions |
ISO |
batimastat results in decreased activity of MAPK1 protein batimastat inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; batimastat inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; batimastat inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of MAPK1 protein] |
CTD |
PMID:15247267 PMID:15319441 PMID:27117977 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases activity multiple interactions |
ISO |
batimastat results in decreased activity of MAPK3 protein batimastat inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; batimastat inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; batimastat inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of MAPK3 protein] |
CTD |
PMID:15247267 PMID:15319441 PMID:27117977 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nts |
neurotensin |
multiple interactions |
ISO |
batimastat inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; batimastat inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15247267 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
ISO |
batimastat inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; batimastat inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; batimastat inhibits the reaction [TAC1 protein results in increased secretion of TGFA protein] |
CTD |
PMID:15319441 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions decreases secretion |
ISO |
batimastat inhibits the reaction [TAC1 protein results in increased secretion of TGFA protein]; batimastat inhibits the reaction [Tetrachlorodibenzodioxin results in increased secretion of TGFA protein] batimastat results in decreased secretion of TGFA protein |
CTD |
PMID:15319441 PMID:27117977 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
decreases activity |
ISO |
batimastat results in decreased activity of TIMP2 protein |
CTD |
PMID:15632106 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
batimastat inhibits the reaction [tributyltin results in increased secretion of TNF protein] |
CTD |
PMID:29532501 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
Canagliflozin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased activity of ACHE protein]; Canagliflozin inhibits the reaction [Scopolamine results in increased activity of ACHE protein] |
CTD |
PMID:27566243 PMID:28837785 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
decreases expression multiple interactions |
EXP |
Canagliflozin results in decreased expression of CHRM1 protein Canagliflozin affects the reaction [Scopolamine results in decreased expression of CHRM1 protein] |
CTD |
PMID:28837785 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
EXP |
Canagliflozin results in increased expression of HAVCR1 |
CTD |
PMID:25130857 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases expression |
EXP |
Canagliflozin results in increased expression of LHB protein |
CTD |
PMID:25289773 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Pth |
parathyroid hormone |
decreases expression |
EXP |
Canagliflozin results in decreased expression of PTH protein |
CTD |
PMID:25289773 |
|
NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Slc5a2 |
solute carrier family 5 member 2 |
decreases activity |
ISO |
Canagliflozin results in decreased activity of SLC5A2 protein |
CTD |
PMID:21128592 |
|
NCBI chr 1:182,847,185...182,853,309
Ensembl chr 1:182,847,106...182,853,306
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of ABCB11 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of ABCC2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of ABCC3 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Cephalothin results in increased expression of BAX protein |
CTD |
PMID:15012731 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Cephalothin results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:15012731 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of FGF15 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of NPC1L1 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of NR5A2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of SLC10A1 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc25a20 |
solute carrier family 25 member 20 |
multiple interactions |
EXP |
Cephalothin binds to and results in decreased activity of SLC25A20 protein; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine] |
CTD |
PMID:18452908 |
|
NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512
|
|
G |
Slc51b |
SLC51 subunit beta |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in decreased expression of SLC51B mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
Cephalothin results in increased expression of TP53 protein |
CTD |
PMID:15012731 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of VDR mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
dorzolamide binds to and results in decreased activity of CA2 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
dorzolamide binds to and results in decreased activity of CA3 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
DuP 697 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein] |
CTD |
PMID:21163909 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases activity |
EXP ISO |
[DuP 697 results in decreased expression of PTGS2] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased abundance of Dinoprostone] DuP 697 results in decreased activity of PTGS2 protein |
CTD |
PMID:19397918 PMID:25451575 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
increases expression |
ISO |
DuP 697 results in increased expression of TNFRSF10A protein |
CTD |
PMID:15572759 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects secretion |
ISO |
DuP 697 affects the secretion of VEGFA protein |
CTD |
PMID:15705899 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
EXP |
eprosartan decreases expression of collagen I-a1 mRNA in high fat high sodium fed SHRSP/A3N rat kidney |
RGD |
PMID:11907153 |
RGD:28912746 |
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
EXP |
eprosartan decreases expression of collagen III mRNA in high fat high sodium fed SHRSP/A3N rat kidney |
RGD |
PMID:11907153 |
RGD:28912746 |
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
EXP |
eprosartan decreases expression of fibronectin mRNA in high fat high sodium fed SHRSP/A3N rat kidney |
RGD |
PMID:11907153 |
RGD:28912746 |
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression |
EXP |
eprosartan decreases expression of plasminogen activator inhibitor -1 mRNA in high fat high sodium fed SHRSP/A3N rat kidney |
RGD |
PMID:11907153 |
RGD:28912746 |
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
EXP |
eprosartan decreases expression of TGFbeta mRNA in high fat high sodium fed SHRSP/A3N rat kidney |
RGD |
PMID:11907153 |
RGD:28912746 |
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
ISO |
Nocodazole results in decreased expression of ABCC2 mRNA; Nocodazole results in decreased expression of ABCC2 protein |
CTD |
PMID:10691972 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
Nocodazole results in increased expression of ABCC3 mRNA |
CTD |
PMID:10691972 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
ISO |
Nocodazole results in increased expression of ACTA2 mRNA 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Nocodazole results in increased expression of ACTA2 mRNA] |
CTD |
PMID:31170432 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ahr |
aryl hydrocarbon receptor |
decreases activity |
ISO EXP |
Nocodazole results in decreased activity of AHR protein |
CTD |
PMID:16611024 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Anapc2 |
anaphase promoting complex subunit 2 |
multiple interactions |
ISO |
Nocodazole promotes the reaction [CCAR1 protein binds to ANAPC2 protein] |
CTD |
PMID:21903591 |
|
NCBI chr 3:8,086,434...8,098,182
Ensembl chr 3:8,086,462...8,098,178
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases localization |
ISO |
Nocodazole inhibits the reaction [Dihydrotestosterone results in increased localization of AR protein] Nocodazole results in decreased localization of AR protein |
CTD |
PMID:20807808 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
Doxorubicin inhibits the reaction [Nocodazole inhibits the reaction [Hydroxyurea results in increased phosphorylation of ATM protein]]; Nocodazole inhibits the reaction [Hydroxyurea results in increased phosphorylation of ATM protein] |
CTD |
PMID:31597699 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
Nocodazole inhibits the reaction [Copper affects the localization of ATP7B protein] |
CTD |
PMID:10982773 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Aurka |
aurora kinase A |
multiple interactions |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased expression of and results in increased phosphorylation of AURKA protein; [bisphenol A analog co-treated with Nocodazole] results in decreased expression of AURKA protein; [bisphenol A co-treated with Nocodazole] results in decreased expression of AURKA protein; MLN8054 inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKA protein] |
CTD |
PMID:24976383 PMID:35041905 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Aurkb |
aurora kinase B |
multiple interactions |
ISO |
4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein |
CTD |
PMID:24976383 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Nocodazole analog results in increased expression of BAX protein |
CTD |
PMID:28412508 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases phosphorylation decreases expression multiple interactions |
ISO |
Nocodazole results in increased phosphorylation of BCL2 protein Nocodazole analog results in decreased expression of BCL2 protein TYMP inhibits the reaction [Nocodazole results in increased phosphorylation of BCL2 protein] |
CTD |
PMID:15907805 PMID:28412508 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
Nocodazole affects the reaction [BIRC5 protein affects the susceptibility to Melphalan] |
CTD |
PMID:16373717 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
multiple interactions increases phosphorylation |
ISO |
[Nocodazole co-treated with Caffeine] results in increased expression of BUB1 protein modified form; chromium hexavalent ion inhibits the reaction [Nocodazole results in increased phosphorylation of BUB1 protein] |
CTD |
PMID:21670593 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
Capza1 |
capping actin protein of muscle Z-line subunit alpha 1 |
multiple interactions |
ISO |
[CAPZA1 protein co-treated with CAPZA2 protein] results in decreased susceptibility to Nocodazole |
CTD |
PMID:22918941 |
|
NCBI chr 2:192,319,696...192,364,755
Ensembl chr 2:192,319,702...192,364,480
|
|
G |
Capza2 |
capping actin protein of muscle Z-line subunit alpha 2 |
multiple interactions |
ISO |
[CAPZA1 protein co-treated with CAPZA2 protein] results in decreased susceptibility to Nocodazole |
CTD |
PMID:22918941 |
|
NCBI chr 4:45,978,142...46,014,032
Ensembl chr 4:45,977,807...46,013,864
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions decreases expression |
ISO |
Nocodazole results in increased cleavage of CASP3 protein [Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein; [Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein; Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]] Nocodazole analog results in decreased expression of CASP3 protein |
CTD |
PMID:21903591 PMID:28412508 PMID:31597699 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
Caspase Inhibitors inhibits the reaction [Nocodazole analog results in increased expression of CASP8 protein modified form] Nocodazole analog results in increased cleavage of CASP8 protein |
CTD |
PMID:28412508 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
Nocodazole analog results in increased cleavage of CASP9 protein |
CTD |
PMID:28412508 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
multiple interactions increases expression |
ISO |
Nocodazole inhibits the reaction [sodium arsenite affects the localization of CCAR1 protein]; Nocodazole promotes the reaction [CCAR1 protein binds to ANAPC2 protein] Nocodazole results in increased expression of CCAR1 protein |
CTD |
PMID:19073175 PMID:21903591 |
|
NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Nocodazole results in increased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnb1 |
cyclin B1 |
increases expression |
ISO |
Nocodazole analog results in increased expression of CCNB1 protein; Nocodazole results in increased expression of CCNB1 protein |
CTD |
PMID:21670593 PMID:28412508 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases expression |
ISO |
Nocodazole analog results in increased expression of CDK1 protein |
CTD |
PMID:28412508 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
multiple interactions |
ISO |
[Nocodazole co-treated with chromium hexavalent ion] results in decreased expression of and results in decreased phosphorylation of CDT1 protein |
CTD |
PMID:21670593 |
|
NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects localization multiple interactions |
ISO EXP |
Nocodazole affects the localization of CFTR protein Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein] |
CTD |
PMID:12529251 PMID:15994425 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chek1 |
checkpoint kinase 1 |
decreases expression |
ISO |
Nocodazole results in decreased expression of CHEK1 protein |
CTD |
PMID:26914363 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Nocodazole inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Nocodazole inhibits the reaction [Quercetin results in increased secretion of CSF2 protein] |
CTD |
PMID:18346843 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Nocodazole inhibits the reaction [benzotriphenylene results in increased expression of and results in increased activity of CYP1A1 protein]; Nocodazole inhibits the reaction [benzotriphenylene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:8190110 PMID:16611024 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
Nocodazole inhibits the reaction [EGF protein results in increased expression of PSA mRNA] |
CTD |
PMID:20807808 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[TYMP co-treated with Nocodazole] results in decreased expression of FASLG mRNA; [TYMP co-treated with Nocodazole] results in decreased expression of FASLG protein |
CTD |
PMID:15907805 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbxo5 |
F-box protein 5 |
multiple interactions |
ISO |
[Nocodazole co-treated with chromium hexavalent ion] results in decreased expression of FBXO5 protein |
CTD |
PMID:21670593 |
|
NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437
|
|
G |
Fis1 |
fission, mitochondrial 1 |
increases expression |
EXP |
Nocodazole results in increased expression of FIS1 protein |
CTD |
PMID:26732598 |
|
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Gmnn |
geminin, DNA replication inhibitor |
multiple interactions |
ISO |
[Nocodazole co-treated with chromium hexavalent ion] results in increased ubiquitination of GMNN protein |
CTD |
PMID:21670593 |
|
NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054
|
|
G |
H2ax |
H2A.X variant histone |
increases expression |
ISO |
Nocodazole results in increased expression of H2AX protein modified form |
CTD |
PMID:26914363 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression |
ISO |
Nocodazole results in decreased expression of HAMP mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Nocodazole results in increased expression of HSPA5 protein |
CTD |
PMID:26732598 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:33377310 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:33377310 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6r |
interleukin 6 receptor |
increases expression |
ISO |
Nocodazole results in increased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases phosphorylation multiple interactions |
ISO |
Nocodazole results in increased phosphorylation of JUN protein TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of JUN protein] |
CTD |
PMID:12221076 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
multiple interactions |
ISO |
Nocodazole inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA] |
CTD |
PMID:20807808 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Lcmt1 |
leucine carboxyl methyltransferase 1 |
decreases response to substance |
ISO |
LCMT1 results in decreased susceptibility to Nocodazole |
CTD |
PMID:17724024 |
|
NCBI chr 1:177,904,119...177,960,111
Ensembl chr 1:177,904,139...177,960,112
|
|
G |
Lzts1 |
leucine zipper tumor suppressor 1 |
affects response to substance |
ISO |
LZTS1 protein affects the susceptibility to Nocodazole |
CTD |
PMID:17349584 |
|
NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein] Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK1 protein] |
CTD |
PMID:15907805 PMID:17822405 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein] Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK3 protein] |
CTD |
PMID:15907805 PMID:17822405 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:12221076 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation multiple interactions |
ISO |
Nocodazole results in increased phosphorylation of MAPK9 protein TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:12221076 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
Nocodazole results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Myt1 |
myelin transcription factor 1 |
increases phosphorylation |
ISO |
Nocodazole results in increased phosphorylation of MYT1 protein |
CTD |
PMID:16611024 |
|
NCBI chr 3:168,890,466...168,950,341
Ensembl chr 3:168,886,089...168,950,341
|
|
G |
Nanog |
Nanog homeobox |
decreases expression |
ISO |
Nocodazole results in decreased expression of NANOG protein |
CTD |
PMID:21559451 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Nocodazole inhibits the reaction [NGF protein affects the localization of NTRK1 protein]; Nocodazole inhibits the reaction [NGF protein affects the localization of RAP1A protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK1 protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK3 protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of RAP1A protein] |
CTD |
PMID:17822405 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Notch1 |
notch receptor 1 |
decreases expression multiple interactions |
ISO |
Nocodazole results in decreased expression of NOTCH1 protein BI 2536 inhibits the reaction [Nocodazole results in decreased expression of NOTCH1 protein]; Doxorubicin inhibits the reaction [Nocodazole promotes the reaction [Hydroxyurea results in decreased expression of NOTCH1 protein]]; Nocodazole promotes the reaction [Hydroxyurea results in decreased expression of NOTCH1 protein]; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]] |
CTD |
PMID:31597699 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
multiple interactions |
ISO |
Nocodazole inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin] |
CTD |
PMID:16174794 |
|
NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049
|
|
G |
Npm1 |
nucleophosmin 1 |
affects phosphorylation |
ISO |
Nocodazole affects the phosphorylation of NPM1 protein |
CTD |
PMID:15190079 |
|
NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645 Ensembl chr X:17,739,941...17,751,645
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
Nocodazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Ntrk1 |
neurotrophic receptor tyrosine kinase 1 |
multiple interactions |
EXP |
Nocodazole inhibits the reaction [NGF protein affects the localization of NTRK1 protein] |
CTD |
PMID:17822405 |
|
NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770
|
|
G |
Optn |
optineurin |
affects localization |
ISO |
Nocodazole affects the localization of OPTN protein |
CTD |
PMID:25096716 |
|
NCBI chr17:73,209,572...73,260,251
Ensembl chr17:73,209,575...73,260,251
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
TYMP inhibits the reaction [Nocodazole results in increased cleavage of PARP1 protein] Nocodazole analog results in increased cleavage of PARP1 protein; Nocodazole results in increased cleavage of PARP1 protein |
CTD |
PMID:15907805 PMID:21903591 PMID:28412508 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Plk1 |
polo-like kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
[Hydroxyurea co-treated with Nocodazole] affects the expression of and affects the phosphorylation of PLK1 protein; Doxorubicin affects the reaction [[Hydroxyurea co-treated with Nocodazole] affects the expression of and affects the phosphorylation of PLK1 protein] Nocodazole results in decreased phosphorylation of PLK1 protein |
CTD |
PMID:31597699 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
decreases expression |
ISO |
Nocodazole results in decreased expression of POU5F1 protein |
CTD |
PMID:21559451 |
|
NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppp2r2a |
protein phosphatase 2, regulatory subunit B, alpha |
decreases response to substance |
ISO |
PPP2R2A results in decreased susceptibility to Nocodazole |
CTD |
PMID:17724024 |
|
NCBI chr15:41,204,659...41,263,924
Ensembl chr15:41,204,200...41,263,924
|
|
G |
Qrich1 |
glutamine-rich 1 |
multiple interactions increases phosphorylation |
ISO |
Genistein inhibits the reaction [Nocodazole results in increased phosphorylation of QRICH1 protein] |
CTD |
PMID:17510977 |
|
NCBI chr 8:109,216,900...109,256,472
Ensembl chr 8:109,217,376...109,261,359
|
|
G |
Rangap1 |
RAN GTPase activating protein 1 |
multiple interactions |
ISO |
Nocodazole results in increased phosphorylation of [SUMO1 protein binds to RANGAP1 protein] |
CTD |
PMID:21646468 |
|
NCBI chr 7:113,224,695...113,250,441
Ensembl chr 7:113,224,703...113,250,438
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
EXP |
Nocodazole inhibits the reaction [NGF protein affects the localization of RAP1A protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of RAP1A protein] |
CTD |
PMID:17822405 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Nocodazole inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein] |
CTD |
PMID:29247640 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Nocodazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
multiple interactions |
ISO |
Nocodazole results in increased phosphorylation of [SUMO1 protein binds to RANGAP1 protein] |
CTD |
PMID:21646468 |
|
NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761
|
|
G |
Tf |
transferrin |
decreases expression |
ISO |
Nocodazole results in decreased expression of TRF protein |
CTD |
PMID:34089742 |
|
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:33377310 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of JUN protein]; TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK8 protein]; TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK9 protein] Nocodazole analog results in increased expression of TP53 protein; Nocodazole results in increased expression of TP53 protein |
CTD |
PMID:12221076 PMID:21559451 PMID:28412508 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tuba1a |
tubulin, alpha 1A |
multiple interactions |
ISO |
Nocodazole inhibits the reaction [TUBA1A protein binds to TUBA1A protein] |
CTD |
PMID:19222062 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tymp |
thymidine phosphorylase |
multiple interactions |
ISO |
[TYMP co-treated with Nocodazole] results in decreased expression of FASLG mRNA; [TYMP co-treated with Nocodazole] results in decreased expression of FASLG protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; TYMP inhibits the reaction [Nocodazole results in increased cleavage of PARP1 protein]; TYMP inhibits the reaction [Nocodazole results in increased phosphorylation of BCL2 protein] |
CTD |
PMID:15907805 |
|
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
Nocodazole results in increased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Pyrantel results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects metabolic processing |
ISO |
CYP2D6 protein affects the metabolism of Pyrantel |
CTD |
PMID:12920490 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Pyrantel results in decreased activity of CYP3A4 protein |
CTD |
PMID:11124226 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:30719803 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in decreased expression of ALB protein] |
CTD |
PMID:30719803 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases hydroxylation |
ISO |
erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Rivaroxaban] |
CTD |
PMID:34189909 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases hydroxylation multiple interactions |
ISO |
CYP3A5 protein results in increased hydroxylation of Rivaroxaban erdafitinib inhibits the reaction [CYP3A5 protein results in increased hydroxylation of Rivaroxaban] |
CTD |
PMID:34189909 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
F10 |
coagulation factor X |
decreases activity |
ISO |
Rivaroxaban results in decreased activity of F10 protein |
CTD |
PMID:16084352 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
EXP |
Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in increased expression of F3 protein]; Rivaroxaban inhibits the reaction [Cisplatin results in increased expression of F3 protein] |
CTD |
PMID:30719803 PMID:36122812 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein]; Rivaroxaban inhibits the reaction [Cisplatin results in increased activity of GPT protein] |
CTD |
PMID:30719803 PMID:36122812 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
multiple interactions |
EXP |
Rivaroxaban inhibits the reaction [Cisplatin results in decreased expression of HSD17B3 mRNA] |
CTD |
PMID:36122812 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsd3b7 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 |
multiple interactions |
EXP |
Rivaroxaban inhibits the reaction [Cisplatin results in decreased expression of HSD3B7 mRNA] |
CTD |
PMID:36122812 |
|
NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; Rivaroxaban inhibits the reaction [Cisplatin results in increased expression of IL1B protein] |
CTD |
PMID:30719803 PMID:36122812 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Rivaroxaban inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein] |
CTD |
PMID:36122812 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
Rivaroxaban inhibits the reaction [Cisplatin results in decreased expression of STAR mRNA] |
CTD |
PMID:36122812 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein] |
CTD |
PMID:30719803 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Rivaroxaban inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Rivaroxaban inhibits the reaction [Cisplatin results in increased expression of TNF protein] |
CTD |
PMID:30719803 PMID:36122812 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
Rivaroxaban inhibits the reaction [Cisplatin results in increased expression of VCAM1 protein] |
CTD |
PMID:36122812 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Htr3a |
5-hydroxytryptamine receptor 3A |
affects activity |
ISO |
Sufentanil affects the activity of HTR3A protein |
CTD |
PMID:18635474 |
|
NCBI chr 8:49,242,018...49,254,475
Ensembl chr 8:49,242,020...49,254,389
|
|
G |
Pomc |
proopiomelanocortin |
decreases expression |
ISO |
Sufentanil results in decreased expression of POMC protein modified form |
CTD |
PMID:15714323 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
|
G |
Dhrs11 |
dehydrogenase/reductase 11 |
decreases activity |
ISO |
Suprofen results in decreased activity of DHRS11 protein |
CTD |
PMID:30926317 |
|
NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Suprofen results in increased expression of GCLC mRNA |
CTD |
PMID:11909699 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Suprofen results in increased expression of GCLM mRNA |
CTD |
PMID:11909699 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:210,347,482...210,367,535
|
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
decreases activity multiple interactions |
ISO |
tenidap results in decreased activity of ALOX5 protein [tenidap results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [tenidap results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:2849922 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Slc26a3 |
solute carrier family 26 member 3 |
decreases activity |
ISO |
tenidap results in decreased activity of SLC26A3 protein |
CTD |
PMID:12651923 |
|
NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:48,023,892...48,064,772
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases response to substance |
ISO |
ABCC1 results in decreased susceptibility to Teniposide |
CTD |
PMID:8968083 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Teniposide results in increased expression of CDKN1A mRNA; Teniposide results in increased expression of CDKN1A protein |
CTD |
PMID:25914138 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases methylation multiple interactions |
ISO |
CYP3A4 protein results in decreased methylation of Teniposide Cyclosporine inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Dexamethasone inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Erythromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Midazolam inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide] |
CTD |
PMID:8114683 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases methylation |
ISO |
CYP3A5 protein results in decreased methylation of Teniposide |
CTD |
PMID:8114683 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:25752796 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:25752796 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
decreases response to substance |
ISO |
FGF2 protein results in decreased susceptibility to Teniposide |
CTD |
PMID:20221717 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Teniposide inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Mir135b |
microRNA 135b |
decreases response to substance |
ISO |
MIR135B mRNA results in decreased susceptibility to Teniposide |
CTD |
PMID:27570640 |
|
NCBI chr13:43,638,857...43,638,953
Ensembl chr13:43,638,857...43,638,953
|
|
G |
Mir196b |
microRNA 196b |
decreases response to substance |
ISO |
MIR196B mRNA results in decreased susceptibility to Teniposide |
CTD |
PMID:27570640 |
|
NCBI chr 4:81,330,487...81,330,571
Ensembl chr 4:81,330,487...81,330,571
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
decreases expression multiple interactions |
ISO |
Teniposide results in decreased expression of MTTP mRNA Teniposide promotes the reaction [CETP protein results in decreased expression of MTTP mRNA] |
CTD |
PMID:25914138 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Teniposide results in decreased expression of MYC mRNA; Teniposide results in decreased expression of MYC protein |
CTD |
PMID:11585056 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions affects localization affects response to substance |
ISO |
NR1H2 mutant form inhibits the reaction [Teniposide results in increased expression of CETP mRNA]; Teniposide promotes the reaction [NR1H2 protein results in increased expression of CETP mRNA] Teniposide affects the localization of NR1H2 protein NR1H2 protein affects the susceptibility to Teniposide |
CTD |
PMID:25914138 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions increases expression affects response to substance |
ISO |
NR1H3 mutant form inhibits the reaction [Teniposide results in increased expression of CETP mRNA]; Teniposide promotes the reaction [NR1H3 protein results in increased expression of CETP mRNA]; Teniposide results in increased expression of and affects the localization of NR1H3 protein Teniposide results in increased expression of NR1H3 mRNA NR1H3 protein affects the susceptibility to Teniposide |
CTD |
PMID:25914138 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
decreases expression |
ISO |
Teniposide results in decreased expression of NRIP1 mRNA; Teniposide results in decreased expression of NRIP1 protein |
CTD |
PMID:25914138 |
|
NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases expression |
ISO |
Teniposide results in decreased expression of ODC1 protein |
CTD |
PMID:11585056 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
Teniposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]; Tretinoin promotes the reaction [Teniposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]] |
CTD |
PMID:25914138 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Teniposide inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue] |
CTD |
PMID:30863990 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of THRB protein |
CTD |
PMID:25752796 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions |
ISO |
TOP2A results in decreased susceptibility to [Cisplatin co-treated with Teniposide] |
CTD |
PMID:11325482 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
|
G |
Aadat |
aminoadipate aminotransferase |
decreases activity |
EXP |
tiagabine results in decreased activity of AADAT protein |
CTD |
PMID:16765940 |
|
NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases expression |
EXP |
Amino Acids, Peptides, and Proteins inhibits the reaction [tiagabine results in increased expression of ABCB1 protein] |
CTD |
PMID:18473823 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression |
EXP |
tiagabine results in increased expression of ABCC1 protein |
CTD |
PMID:18473823 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
tiagabine results in increased expression of ABCC2 protein |
CTD |
PMID:18473823 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
tiagabine results in decreased activity of CYP19A1 protein |
CTD |
PMID:17959350 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Kyat1 |
kynurenine aminotransferase 1 |
decreases activity |
EXP |
tiagabine results in decreased activity of KYAT1 protein |
CTD |
PMID:16765940 |
|
NCBI chr 3:33,857,407...33,891,153
Ensembl chr 3:13,459,591...13,493,355
|
|
G |
Slc6a1 |
solute carrier family 6 member 1 |
decreases activity |
ISO |
tiagabine results in decreased activity of SLC6A1 protein |
CTD |
PMID:15788781 |
|
NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293
|
|
|
G |
Cbr1 |
carbonyl reductase 1 |
increases reduction |
ISO |
CBR1 protein results in increased reduction of tiaprofenic acid |
CTD |
PMID:28322780 |
|
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
tiaprofenic acid results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions increases glucuronidation |
ISO |
tiaprofenic acid inhibits the reaction [UGT2B7 protein results in increased chemical synthesis of aldosterone 18-glucuronide]; tiaprofenic acid inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone] UGT2B7 protein alternative form results in increased glucuronidation of tiaprofenic acid; UGT2B7 protein results in increased glucuronidation of tiaprofenic acid |
CTD |
PMID:8423545 PMID:8517101 PMID:19740398 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases expression |
ISO |
Ticrynafen results in increased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity multiple interactions |
ISO |
Ticrynafen results in decreased activity of CYP2B6 protein Ticrynafen inhibits the reaction [CYP2B6 protein results in increased chemical synthesis of hydroxybupropion]; Ticrynafen inhibits the reaction [CYP2B6 protein results in increased metabolism of Bupropion] |
CTD |
PMID:21915887 |
|
NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Ticrynafen results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Ticrynafen results in increased expression of HMOX1 mRNA |
CTD |
PMID:18227147 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Ticrynafen results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Ticrynafen results in increased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
Ticrynafen results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Ticrynafen results in increased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ren |
renin |
increases activity |
ISO |
Ticrynafen results in increased activity of REN protein |
CTD |
PMID:6756707 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
decreases activity multiple interactions |
ISO |
Ticrynafen results in decreased activity of SLC12A2 protein Ticrynafen inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium] |
CTD |
PMID:29959396 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Ticrynafen results in increased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Ticrynafen results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
ISO |
Ticrynafen results in increased expression of UGT1A1 mRNA |
CTD |
PMID:18227147 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
thiaton results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
thiaton inhibits the reaction [Indomethacin results in increased activity of MPO protein] |
CTD |
PMID:11855677 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
thiaton inhibits the reaction [Indomethacin results in increased activity of NOS2 protein] |
CTD |
PMID:11855677 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|